Results 191 to 200 of about 26,259 (260)

Sequential Use of Recombinant Porcine Factor VIII and Early Emicizumab in Acquired Hemophilia A: A Case Series

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder requiring prompt hemostatic control and sustained prevention of rebleeding. Recombinant porcine factor VIII (rpFVIII, susoctocog alfa) controls acute bleeding, while emicizumab provides prophylaxis. Real‐world data on their sequential use are limited.
Yusuke Yamada, Takashi Onaka, Kazunori Imada   +2 more
wiley   +1 more source

Bruton Tyrosine Kinase Inhibition in Combination With Bispecific Antibodies for Richter's Syndrome: A Report of Two Cases and Mini Review. [PDF]

Cureus
Hane BC, Hoffmann M, Zhang D, Chopra S, Bennett J.   +4 more
europepmc   +1 more source

Effectiveness and Safety of Prophylactic Low‐Dose Emicizumab in Young Children With Hemophilia A: A Multicenter Retrospective Study

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background Real‐world data on low‐dose emicizumab in young children with hemophilia A are limited. Methods This multicenter retrospective study included 26 children (median age: 2.2 years) receiving individualized low‐dose emicizumab (2019–2025).
Guichi Zhou, Liya He, Chunyan Wang, Yashuang Deng, Dong Peng, Zhaonan Liu, Sixi Liu, Xiaoying Fu, Ying Wang, Xiaoqin Feng   +9 more
wiley   +1 more source

Recent Advances in Antibody Therapy for Alzheimer's Disease: Focus on Bispecific Antibodies. [PDF]

Int J Mol Sci
Yang HM.
europepmc   +1 more source

Co-phagocytosis by bispecific antibodies, a novel strategy for targeted degradation of soluble factors in the tumor microenvironment. [PDF]

Cancer Lett
Fan Z.
europepmc   +1 more source

Bispecific Antibodies-A New Hope for Patients with Diffuse Large B-Cell Lymphoma. [PDF]

J Clin Med
Mihaila RG, Todor SB.
europepmc   +1 more source

Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study. [PDF]

Blood Adv
Peña M, Losi G, Navarro V, Qualls DA, Crombie JL, Mariotti J, Bramanti S, Fabbri N, Serna Á, Serroukh YIM, Balaguer-Rosselló A, Van Der Poel MWM, Hsu YT, Jiménez-Ubieto A, McKinnely C, López-Corral L, Panizo C, Pérez-Simón JA, Rovira M, Saldaña R, Kwon M, Solano C, Valcárcel D, Pascual-Cascón MJ, Noriega V, Sanz J, Sánchez-Salinas A, Jurado M, Calbacho M, Bento L, Albo López C, Perera M, Heras I, Guerreiro M, Balsalobre P, Armand P, Sureda A, Mussetti A.   +37 more
europepmc   +1 more source

Shooting the messenger: Ecosystem approaches in haematology

HemaSphere, Volume 10, Issue 8, August 2026.
Stephen P. Hibbs
wiley   +1 more source

Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of <i>in vivo</i> CAR-T platforms. [PDF]

Front Immunol
He L, Sun Y, Ma B, Lang G, Wen J, Blumenschein GR, Ma H.   +6 more
europepmc   +1 more source

Therapeutic success and epidemiological failure in hematology

HemaSphere, Volume 10, Issue 8, August 2026.
Pierre Sujobert
wiley   +1 more source